Health Care·Pharmaceuticals·$547.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.80 | N/A | +0.94% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $2.80 | N/A | +0.94% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to long-term growth. They acknowledged ongoing market challenges but remained cautiously optimistic about future performance.
We are pleased with our EPS performance this quarter.
Our focus remains on long-term growth despite current market challenges.
Johnson & Johnson's earnings report shows a positive surprise in EPS, indicating better-than-expected profitability. However, the lack of revenue data and guidance leaves some uncertainty about future performance. The stock reaction is currently unavailable, which may reflect investor caution amidst broader market conditions.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CITIGROUP INC
Oct 14, 2025